Trial Profile
A phase1 study of Hydroxypropyl-beta-cyclodextrin(HP-beta-CyD)-adjuvanted influenza split vaccine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Influenza-split-vaccine Kitasato Daiichi Sankyo Vaccine (Primary) ; Influenza HA split vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- 04 Jun 2022 Results published in the Vaccine
- 07 Aug 2018 Status changed from not yet recruiting to completed.
- 06 Sep 2017 New trial record